

Leukemia

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03289182 ML39600

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.

Hoffmann-La Roche
Sponsor

Phase

NCT03289182 ML39600
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 19 Years

Healthy Volunteers
No
